2019
Minimal Residual Disease in AML can be Monitored Utilizing Cell-Free DNA DOWNLOAD ⟶
Comparison of LymphoTrack® Assays – MiSeq® and Flow Cytometry for Clonality and Minimum Residual Disease Assessment in Multiple Myeloma DOWNLOAD ⟶
Small Customizable Next-Genera5on Sequencing Based Target-Capture Panels in a Clinical Environment Can Detect Variant Muta5ons at Frequencies as Low as 0.5% DOWNLOAD ⟶
Assessment of Minimal Residual Disease in Pa3ents with Acute Myeloid Leukemia by Monitoring FLT3 and NPM1 Mutations DOWNLOAD ⟶
Detection of Clonality in Clinical Specimens from Suspected B-cell Malignancies using ComprehensiveIGH (FR1/2/3) LymphoTrack® MiSeq® and PGM® Assays DOWNLOAD ⟶
Development of LymphoTrack® Bioinformatics Methods: Clonality Testing, Somatic Hypermutation and Minimal Residual Disease DOWNLOAD ⟶
Validation and clinical implementation of next generation sequencing for routine IGH and TCRG clonality assessment DOWNLOAD ⟶
Next-Generation Sequencing for Detection of Clonal TRG Gene Rearrangements Shows Improved Specificity and Positive Predictive Value Compared to Fragment Analysis Using BIOMED-2 Primers and Capillary Electrophoresis DOWNLOAD ⟶
Clinical Assessment of Chronic Lymphocytic Leukemia (CLL) Samples for Somatic Hypermutation Status by Next-Generation Sequencing and Sanger Sequencing DOWNLOAD ⟶
Development of an NGS Assay for IGK that can be combined with IGH for Identifying Clonal Populations in Lymphoid Malignancies DOWNLOAD ⟶
Looking for Product Documents? Try our New Document Search Feature ⟶